A $7.15 million class settlement benefiting former New England Biolabs Inc. employees received final court approval, resolving a lawsuit saying they were forced to sell their stock in the genomic research company at an unfair price.
The settlement is slated to give an average gross recovery of $89,000 for each of about 80 people who had their company stock liquidated between September 2017 and September 2021. Workers say the deal represents about 42% of their potential damages.
- Judge Richard G. Stearns signed the final approval order Thursday in the US District Court for the District of Massachusetts
- Stearns also awarded ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.